Recent developments in hemoglobin-based oxygen carriers--an update on clinical trials.
Considerable progress has been made in the development of the hemoglobin based oxygen carriers (HBOCs), with a number of products in the final stages of clinical development prior to licensing application. This follows many years of concentrated study. Although there are limitations to the clinical use of the currently studied HBOCs, there are a number of advantages that suggest that these products will have an important role in future clinical practice. It is anticipated that these products will be commercially available within two years.
Carmichael
F J
FJ
Hemosol, Inc, Toronto, Ont., Canada. lcarmichael@hemosol.com
D001802:Blood Substitutes / Q000009:adverse effects / Q000592:standards / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D006454:Hemoglobins; D006801:Humans; D010100:Oxygen / Q000378:metabolism
D001802:Blood Substitutes; D006454:Hemoglobins; D010100:Oxygen